Main Menu

Pharmazen

Started by Minimoke, Jun 26, 2022, 05:05 AM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

lorraina

PharmaZen Limited Press Release
19 December 2024
Christmas and almost the end of another financial year has rolled around fast in 2024. At Board level
we farewelled Ken Fergus last month which followed Peter Dobbs retirement in June and the
appointment of Jessie Chan in February. So, this is my first letter to Shareholders in what has been a
challenging year, featuring positives and negatives in equal measure in your Company's progress.
Waitaki continues to adapt to changed market circumstances, both in the form of valuable new
opportunities whilst working to mitigate ongoing raw material supply challenges. As you would
expect, cash is being very carefully prioritised to the highest value opportunities across product
development, market development and new manufacturing facilities.
The Board is grateful for Craig's leadership and energy stepping up to the short-term challenges while
not losing sight of the long-term opportunities. It is also appropriate to acknowledge the huge efforts
this year of all staff, who tirelessly meet often changing customer and shipping deadlines, without
losing sight of quality and safety.
I will provide a further update in March with a detailed snapshot of 2024 financial performance. Until
then, I thank you for your support and wish you all a joyous holiday period and a prosperous, positive
2025.
Vincent Pooch
Chair of PharmaZen Limited

BlackPeter

Quote from: lorraina on Dec 19, 2024, 12:34 PMPharmaZen Limited Press Release
19 December 2024
Christmas and almost the end of another financial year has rolled around fast in 2024. At Board level
we farewelled Ken Fergus last month which followed Peter Dobbs retirement in June and the
appointment of Jessie Chan in February. So, this is my first letter to Shareholders in what has been a
challenging year, featuring positives and negatives in equal measure in your Company's progress.
Waitaki continues to adapt to changed market circumstances, both in the form of valuable new
opportunities whilst working to mitigate ongoing raw material supply challenges. As you would
expect, cash is being very carefully prioritised to the highest value opportunities across product
development, market development and new manufacturing facilities.
The Board is grateful for Craig's leadership and energy stepping up to the short-term challenges while
not losing sight of the long-term opportunities. It is also appropriate to acknowledge the huge efforts
this year of all staff, who tirelessly meet often changing customer and shipping deadlines, without
losing sight of quality and safety.
I will provide a further update in March with a detailed snapshot of 2024 financial performance. Until
then, I thank you for your support and wish you all a joyous holiday period and a prosperous, positive
2025.
Vincent Pooch
Chair of PharmaZen Limited

Sounds like a happy chair addressing undemanding share holders. Did he write that after the Christmas Function - or is this the way they keep the market informed?

Minimoke

Quote from: BlackPeter on Dec 19, 2024, 01:31 PMSounds like a happy chair addressing undemanding share holders. Did he write that after the Christmas Function - or is this the way they keep the market informed?
Its not really an "update" - so I dont know what his "further" one will be.

The moment you see "safety" in an announcement you know the corporate mumbu jumbo deflections are in full swing.

Sideshow Bob

Terrible announcement - waste of time with no meaningful info.

What a way to introduce yourself as the new chairman.
"Mayor Quimby Even Released Sideshow Bob — A Man Twice Convicted Of Attempted Murder. Can You Trust A Man Like Mayor Quimby? Vote Sideshow Bob For Mayor."

Doozer

While it is disappointing to get no news and probably means a poor result, I think Vincent Pooch is a very good operator and a huge upgrade on the previous chair. Expecting a lot more clarity in March.

Monty

Appalling lack of detail, symptomatic of the previous chairs reports.

Nothings changed.  Expect to read excuses for all the initiatives reported at the last AGM